Learn About End-Stage Renal Disease (ESRD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Mayo Clinic
Wisit Cheungpasitporn is a Nephrologist in Rochester, Minnesota. Dr. Cheungpasitporn is rated as an Elite provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). His top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Magnesium Deficiency, Kidney Transplant, and Aortic Valve Replacement. Dr. Cheungpasitporn is currently accepting new patients.
Emory University Hospital Midtown Campus
Janice Lea is a Nephrologist in Atlanta, Georgia. Dr. Lea has been practicing medicine for over 37 years and is rated as an Elite provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). Her top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Renovascular Hypertension, Nephrosclerosis, and Kidney Transplant.
Mayo Clinic Health System-Southwest Minnesota Region
Charat Thongprayoon is a Nephrologist in Mankato, Minnesota. Dr. Thongprayoon is rated as an Elite provider by MediFind in the treatment of End-Stage Renal Disease (ESRD). His top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Magnesium Deficiency, Kidney Transplant, and Aortic Valve Replacement. Dr. Thongprayoon is currently accepting new patients.
Summary: Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed ...
Summary: The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).